Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:16 PM
Ignite Modification Date:
2025-12-24 @ 11:16 PM
NCT ID:
NCT00976456
Eligibility Criteria:
Inclusion Criteria:
* Stage IIIb and IV NSCLC, excluded squamous cell NSCLC
* Age ≥ 65 years
* ECOG 0-2
Exclusion Criteria:
* Mixed, non-small cell and small cell tumours or mixed adenosquamous carcinomas with a predominant squamous component
* History of haemoptysis
* Evidence of tumour invading major blood vessels on imaging
* Radiotherapy within 28 days prior to enrolment
* Patients who are unable to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than an aspirin dose ≤ 1.3 grams per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam)
* Current or recent (within 10 days of first dose of bevacizumab) use of full-dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes. Prophylactic use of anticoagulants is allowed
* Clinically significant (i.e. active) cardiovascular disease for example CVA (≤6 months before enrolment), myocardial infarction (≤6 months before enrolment), unstable angina, CHF NYHA Class ≥II, serious cardiac arrhythmia requiring medication during the study and might interfere with regularity of the study treatment, or not controlled by medication
* Non-healing wound, active peptic ulcer or bone fracture
* History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
65 Years
Study:
NCT00976456
Study Brief:
Protocol Section:
NCT00976456